Since GPR56 expression is crucial for cell survival and cell adhesion ability for the BM niche in EVI1high AML cells15, we constructed several PIP compounds that target the EVI1-binding sequence within the GPR56 promoter, which are predicted to inhibit binding of EVI1 to the GPR56 promoter and suppress GPR56 expression. The gene discussed is RUNX1; the disease is acute myeloid leukemia.